rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    APGE
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Jefferies Highlights Three Biotech Stocks With Blockbuster Potential

      Investing.com -- Jefferies identified three biotechnology stocks that appear undervalued with strong commercial prospects despite a challenging macro environment. The firm noted that rising interest rates are pressuring small and mid-cap biotech companies, potentially shifting investor focus toward late-stage and commercial-stage names. All three of the highlighted stocks are positioned to launch products with significant peak sales potential.

      Sep 30Yahoo FinanceAPGE
      Is AbbVie (ABBV)’s $10.9 Billion Apogee Therapeutics (APGE) Deal the Next Catalyst for Growth?

      On September 3, AbbVie Inc. (NYSE:ABBV) finalized its acquisition of clinical-stage biotech Apogee Therapeutics, Inc. (NASDAQ:APGE) for $135.11 per share in cash. The $10.9 billion buyouts immediately fold Apogee’s promising inflammatory and immunology (I&I) pipeline into AbbVie’s commercial engine. On the exact same day, AbbVie separately reported positive Phase 3 Cervino trial results for its […]

      Sep 9Yahoo FinanceAPGEABBV
      Apogee Therapeutics Completes Merger and Plans Nasdaq Delisting

      Detailed price information for Apogee Therapeutics Inc (APGE-Q) from The Globe and Mail including charting and trades.

      Sep 4The Globe and MailAPGE
      AbbVie seals $11B acquisition of Apogee Therapeutics (ABBV:NYSE)
      Sep 3Seeking AlphaAPGEABBV
      AbbVie Completes Acquisition of Apogee Therapeutics

      AbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Apogee Therapeutics, Inc. (NASDAQ: APGE). With completion of the acquisition, Apogee is now part of AbbVie. Under the terms of the agreement, Apogee shareholders received $135.11 per share in cash, for a total equity value of approximately $10.9 billion.

      Sep 3Yahoo FinanceAPGEABBV
      AbbVie Closes $10.9 Billion Acquisition of Apogee Therapeutics

      AbbVie (ABBV) said Thursday that it has completed its acquisition of Apogee Therapeutics (APGE), val

      Sep 3Yahoo FinanceAPGE
      Apogee Therapeutics stock hits all-time high at 134.89 USD
      Aug 26Investing.comAPGE

      This is the newest page. Registered accounts read further back.